S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Forecast, Price & News

$0.22
-0.01 (-4.33%)
(As of 09/20/2023 ET)
Compare
Today's Range
$0.22
▼
$0.23
50-Day Range
$0.21
▼
$0.31
52-Week Range
$0.10
▼
$0.32
Volume
208,279 shs
Average Volume
462,031 shs
Market Capitalization
$17.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

VBLT Price History

VBLT Stock News Headlines

September 18, 2023 | americanbankingnews.com
Vascular Biogenics (NASDAQ:VBLT) Coverage Initiated by Analysts at StockNews.com
September 17, 2023 | americanbankingnews.com
Short Interest in Vascular Biogenics Ltd. (NASDAQ:VBLT) Expands By 46.8%
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 9, 2023 | finance.yahoo.com
Vascular Biogenics Rises on Presentation Hype
September 6, 2023 | finance.yahoo.com
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
August 28, 2023 | businesswire.com
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
August 28, 2023 | businesswire.com
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
August 14, 2023 | finance.yahoo.com
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
July 23, 2023 | fool.com
Vascular Biogenics (NASDAQ: VBLT)
May 15, 2023 | finance.yahoo.com
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
April 4, 2023 | benzinga.com
Vascular Biogenics Stock (NASDAQ:VBLT), Dividends
March 17, 2023 | finance.yahoo.com
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)
March 14, 2023 | finance.yahoo.com
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 9, 2023 | finance.yahoo.com
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
February 27, 2023 | prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLT
February 23, 2023 | technews.tmcnet.com
VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders
February 23, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. Merger
February 23, 2023 | marketwatch.com
Vascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLT
February 23, 2023 | msn.com
Vascular Biogenics rises 85% on all-stock merger deal with Notable Labs
February 23, 2023 | investorplace.com
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
February 16, 2023 | finance.yahoo.com
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
November 10, 2022 | finance.yahoo.com
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
September 2, 2022 | finance.yahoo.com
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
September 1, 2022 | finance.yahoo.com
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
September 1, 2022 | finance.yahoo.com
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
August 2, 2022 | marketwatch.com
Vascular Biogenics Cutting About 35% of Staff >VBLT
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings
8/14/2023
Today
9/20/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
CUSIP
N/A
CIK
1603207
Web
www.vblrx.com
Phone
(728) 993-5000
Fax
972-8993-5001
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,300,000.00
Net Margins
N/A
Pretax Margin
-3,317.05%
Return on Equity
-73.45%
Return on Assets
-54.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.63
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$660,000.00
Price / Sales
26.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
0.69

Miscellaneous

Outstanding Shares
77,640,000
Free Float
72,881,000
Market Cap
$17.16 million
Optionable
Optionable
Beta
0.82
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Prof. Dror Harats M.D. (Age 66)
    CEO & Director
    Comp: $444.33k
  • Mr. Samuel Backenroth (Age 39)
    Chief Financial Officer
    Comp: $410k
  • Dr. Eyal Breitbart Ph.D. (Age 56)
    Sr. VP of Research & Operations
  • Advocate Ayelet Horn (Age 52)
    Gen. Counsel
  • Dr. Erez Feige M.B.A. (Age 49)
    Ph.D., Sr. VP of Bus. Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













VBLT Stock - Frequently Asked Questions

How have VBLT shares performed in 2023?

Vascular Biogenics' stock was trading at $0.12 at the beginning of 2023. Since then, VBLT shares have increased by 84.2% and is now trading at $0.2211.
View the best growth stocks for 2023 here.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in August. As of August 31st, there was short interest totaling 296,700 shares, an increase of 46.8% from the August 15th total of 202,100 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.5% of the shares of the stock are short sold.
View Vascular Biogenics' Short Interest.

When is Vascular Biogenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VBLT earnings forecast.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by many different retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%).

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.22.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $17.16 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-32,300,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -